Use of medication and quality of life among patients with COPD

Respiratory Medicine

Volumn 100, Issue 3, 2006, Pages 487-495

  Esteban, Cristóbal ^a   Moraza, Javier ^a   Quintana, Jose M ^a   Aburto, Mirian ^a   Capelastegui, Alberto ^a  

^a HOSPITAL DE GALDAKAO   (Spain)

Author keywords

COPD; Health related quality of life; Inhaled corticosteroids; Treatment

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; THEOPHYLLINE;

AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DISEASE SEVERITY; DYSPNEA; FEMALE; FORCED EXPIRATORY VOLUME; HEALTH SERVICE; HUMAN; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; SPIROMETRY;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; AGED; CROSS-SECTIONAL STUDIES; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE; QUESTIONNAIRES;

EID: 32644432873     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2005.06.005     Document Type: Article

References (25)

1. American Thoracic Society Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease Am J Respir Crit Care Med 152 Suppl 1995 S77-S120
2. BTS Guidelines for the Management of Chronic Obstructive Pulmonary Disease The COPD Guidelines Group of the Standards of Care Committee of the BTS Thorax 52 Suppl. 5 1997 S1-S28
3. N.M. Siafakas P. Vermiere N.B. Pride et. al. on behalf of the Task Force Optimal assessment and management of chronic obstructive pulmonary disease (COPD) Eur Respir J 8 1995 1398-1420
4. R.A. Pauwels A.S. Buist P.M.A. Calverley C.R. Jenkins S.S. Hurd on behalf of the GOLD Scientific Committee Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: NHLBI Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop Summary Am J Respir Crit Care Med 163 2001 1256-1276
5. The lung health study research group Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease New Engl J Med 343 2000 1902-1909
6. R.A. Pauwels National and international guidelines for COPD. The need for evidence Chest 117 2000 S20-S22
7. M. Rudolf The reality of drug use in COPD. The European perspective Chest 117 2000 S29-S32
8. J. de Miguel J.L. Izquierdo J.M. Rodríguez P. de Lucas J. Molina Drug treatment of chronic obstructive pulmonary disease on two levels of patient care: Degree of compliance with recommended protocols Arch Bronconeumol 39 2003 195-202
9. M. Miravitlles C. Mayordomo M. Artés L. Sánchez-Agudo F. Nicolau J.L. Segú Treatment of chronic obstructive pulmonary disease and its exacerbations in general practice Respir Med 93 1999 173-179
10. G. Boyd A.H. Morice J.C. Pounsford M. Siebert N. Peslis Crawford C on the behalf of an international study group An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD) Eur Respir J 10 1997 815-821
11. C. Jackevicius D.P. Joyce S. Kesten K.R. Chapman Prehospitalization inhaled corticosteroid use in patients with COPD or asthma Chest 111 1997 296-302
12. S. Kesten A.S. Rebuck K.R. Chapman Trends in asthma and chronic obstructive pulmonary disease therapy in Canada, 1985-1990 J Allergy Clin Immunol 92 1993 499-506
13. A.E. Van Andel C. Reisner S.S. Menjoge T.J. Witek Analysis of inhaled corticosteroid and oral theophylline use among patients with stable COPD from 1987-1995 Chest 115 1999 703-707
14. C.M. Fletcher P.C. Elmes C.H. Wood The significance of respiratory symptoms and the diagnosis of chronic bronchitis in a working population Br Med J 2 1959 257-266
15. J. Sanchis Normativa para la espirometría forzada: Grupo de trabajo de la SEPAR para la práctica de la espirometría clínica Arch Bronconeumol 25 1989 132-142
16. P.H. Quanjer G.J. Tammeling J.E. Cotes O.F. Pedersen R. Peslin J.C. Yernault Lung volumes and forced ventilatory flows. Report working party standardization of lung function test, European Community for Steel and Coal. Official statement of the European Respiratory Society Eur Respir J 16 1993 5-40
17. J. Alonso L. Prieto M. Ferrer et. al. Testing the measurement properties of the Spanish version of the SF-36 health survey among male patients with chronic obstructive pulmonary disease J Clin Epidemiol 51 1998 1087-1094
18. P.W. Jones F.H. Quirk C.M. Baveystock The St George's Respiratory Questionnaire Respir Med 85 Suppl. B 1991 25-31
19. M. Ferrer J. Alonso L. Prieto et. al. Validity and reliability of the St. George's Respiratory Questionnaire after adaptation to a different language and culture: The Spanish example Eur Respir J 9 1996 1160-1166
20. N. Roche T. Lepage J. Bourcereau P. Terrioux Guidelines versus clinical practice in the treatment of chronic obstructive pulmonary disease Eur Respir J 18 2001 903-908
21. M. Miravitlles J.L. Alvarez-Sala R. Lamarca et. al. Treatment and quality of life in patients with chronic obstructive pulmonary disease Qual Life Res 11 2002 329-338
22. P.S. Burge P.M.A. Carverley P.W. Jones S. Spencer J.A. Anderson T.L. Maslen On behalf of the ISOLDE study investigators Randomised, double-blind, placebo-controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial Br Med J 320 2000 1297-1303
23. M. Ferrer J. Alonso J. Morera et. al. for the Quality of Life of Chronic Obstructive Pulmonary Disease Study Group Chronic obstructive pulmonary disease stage and health related quality of life Ann Intern Med 127 1997 1072-1079
24. D.D. Sin J.V. Tu Inhaled corticosteroids and the risk of mortality and readmission in elderly patients with chronicobstructive pulmonary disease Am J Respir Crit Care Med 164 2001 580-584
25. I. Otero M. Blanco C. Montero P. Valino H. Verea The epidemiology of COPD and asthma exacerbations in a general hospital Arch Bronconeumol 38 6 2002 256-262